Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome ...

Colorectal cancer rates are rising in younger adults. Learn prevention strategies from screening to lifestyle changes that ...

The Series C round – co-led by Omega Funds and TCGX ... cells from a destructive to a healing state and inhibiting complement-mediate inflammation. Cambridge, Massachusetts-based Aviceda ...

The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.

This important study provides solid evidence that glucosylceramide synthase (GlcT), a rate-limiting enzyme for glycosphingolipid (GSL) production, plays a role in the differentiation of intestinal ...

This study provides a potentially useful investigation into the positive role of BDNF/TrkB signaling in implanted dental pulp stem cells to enhance dentin regeneration in the context of dental caries.

Pleasant Valley’s Devon Bush (4) controls the ball against Easton’s Molly Grifone during the District 11 3A girls lacrosse ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

It was launched in Black and White colours. Connectivity options on the Nothing Phone 2a Special Edition include Wi-Fi 802.11 a/b/g/n/ac, GPS, and USB Type-C with active 4G on both SIM cards. Sensors ...